203 related articles for article (PubMed ID: 23169230)
1. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
Giménez de Béjar V; Carballo-Cordero M
Rev Neurol; 2012; 55 Suppl 1():S25-9. PubMed ID: 23169230
[TBL] [Abstract][Full Text] [Related]
2. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
3. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
4. [Candidate patient for subcutaneous apomorphine injection].
Chacón JR; Mata M
Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
Pot C; Oppliger R; Castillo V; Coeytaux A; Hauser C; Burkhard PR
Neurology; 2005 Jan; 64(2):392-3. PubMed ID: 15668455
[No Abstract] [Full Text] [Related]
6. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Grandas FJ; Sesar-Ignacio Á
Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
Grandas F
Expert Rev Neurother; 2013 Dec; 13(12):1343-53. PubMed ID: 24160681
[TBL] [Abstract][Full Text] [Related]
8. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease.
van Laar T; van der Geest R; Danhof M; Boddé HE; Goossens PH; Roos RA
Clin Neuropharmacol; 1998; 21(3):152-8. PubMed ID: 9617506
[TBL] [Abstract][Full Text] [Related]
9. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
[TBL] [Abstract][Full Text] [Related]
10. Apomorphine nodules in Parkinson's disease: best practice considerations.
Todd A; James CA
Br J Community Nurs; 2008 Oct; 13(10):457-63. PubMed ID: 19057470
[TBL] [Abstract][Full Text] [Related]
11. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
van Laar T; Postma AG; Drent M
Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477
[No Abstract] [Full Text] [Related]
12. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.
Poltawski L; Edwards H; Todd A; Watson T; Lees A; James CA
Mov Disord; 2009 Jan; 24(1):115-8. PubMed ID: 19006068
[TBL] [Abstract][Full Text] [Related]
14. Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease.
Cavallieri F; Fraix V; Meoni S; Krack P; Moro E; Castrioto A
J Neurol Sci; 2019 Sep; 404():44-46. PubMed ID: 31325667
[No Abstract] [Full Text] [Related]
15. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
Müller T
Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
[TBL] [Abstract][Full Text] [Related]
16. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
Salazar G; Martín J; Fragoso M; Font MA
Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210
[No Abstract] [Full Text] [Related]
17. [Apomorphine in treatment of Parkinson's disease with fluctuations].
Zaleska B; Domzał T
Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
[TBL] [Abstract][Full Text] [Related]
18. [Idiopathic Parkinson's disease: practical hints for the treatment].
Ludin HP
Praxis (Bern 1994); 2005 Jul; 94(30-31):1147-50. PubMed ID: 16117469
[TBL] [Abstract][Full Text] [Related]
19. Use of apomorphine in clinical practice.
MacMahon DG
Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
[No Abstract] [Full Text] [Related]
20. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
Borgemeester RWK; van Laar T
Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
